



Flexion Therapeutics, Inc.
Investor Relations Department
10 Mall Road
Suite 301
Burlington, MA 01803
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: FLXN

Last Trade:	24.82
Trade Time:	4:00 PM ET Dec 12, 2017
Change:	-0.09 ▼ (-0.361%)
Day Range	24.18 - 25.28
52-Week Range	16.51 - 32.25
Volume	1,106,630

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA).

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Dec 11, 2017
[Flexion Therapeutics Announces Appointment of Scott Kelley, M.D. as Chief Medical Officer](#)

Dec 7, 2017
[Flexion Therapeutics Enrolls First Patient in Phase 2 Pharmacokinetics and Safety Study of ZILRETTA™ \(triamcinolone acetonide extended-release injectable suspension\) in Bilateral Osteoarthritis of the Knee](#)

Dec 6, 2017
[Flexion Therapeutics to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference](#)

Dec 4, 2017
[Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)

Nov 28, 2017
[Flexion Therapeutics to Present at Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference](#)

Upcoming Events [\[View all \]](#)

Dec 14, 2017 8:30 AM ET
[BMO Capital Markets: Prescriptions for Success Healthcare Conference](#)

Financials [\[View all \]](#)

[Third Quarter Financial Results](#)

Mar 10, 2017
[Annual Report \(10-K\)](#)

Apr 28, 2017
[Proxy Statement \(DEF 14A\)](#)

Nov 6, 2017
[Quarterly Report \(10-Q\)](#)

Aug 8, 2017
[Quarterly Report \(10-Q\)](#)

May 5, 2017
[Quarterly Report \(10-Q\)](#)